Olmesartan Medoxomil/Amlodipine/Hct Accord (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hct Accord, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension in adults, often when a single agent does not provide adequate blood pressure control.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hct Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil/Amlodipine/HCT combines three agents that act on the renin‑angiotensin‑aldosterone system and vascular smooth muscle to lower blood pressure. Indications include: - Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Resistant hypertension: helps achieve target pressures in patients who require multiple agents. - Hypertensive patients with concomitant edema: amlodipine’s vasodilatory effect counteracts fluid retention. - Hypertension with volume overload: hydrochlorothiazide adds diuretic action to improve control.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema - Headache - Fatigue - Cough - Increased uric acid levels

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Electrolyte disturbances (e.g., hyponatremia, hypokalemia) - Acute kidney injury - Liver function abnormalities - Severe skin reactions such as Stevens‑Johnson syndrome

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: assess kidney function and adjust diuretic dose if needed. - Hepatic disease: use with caution; monitor liver enzymes. - Electrolyte balance: check serum potassium and sodium regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Olmesartan Medoxomil/Amlodipine/HCT may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal failure. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: increased risk of lithium toxicity. - Antidiabetic agents: may enhance hypoglycaemic effect. - Alcohol: additive hypotensive effect. - Antacids containing aluminium or magnesium: may reduce absorption of olmesartan.